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rate increases with increasing lesion size, being 73 % for 
lesions larger than 10 mm.
Conclusion Tracker-based MR–TRUS fusion biopsy with 
local reference augmentation is feasible, especially for 
lesions with an MR maximum diameter of at least 10 mm 
or PIRADS 5 lesions. If this is not the case, we recommend 
in-bore MR-guided biopsy.
Keywords MR–US fusion · Prostate cancer · Biopsy · 
PIRADS
Introduction
An elevated or rising PSA followed by systematic (on aver-
age 12 core) transrectal ultrasound (TRUS)-guided biopsy 
(USgBx) is the currently internationally accepted diag-
nostic procedure to detect prostate cancer and determine 
patient management [1]. TRUS cannot localize malignant 
tissue and is merely used to guide systematic biopsies. 
USgBx has a low sensitivity (40 %) [2–4], causing three 
problems: (1) Significant cancers can be missed or under-
estimated; (2) there is unnecessary overtreatment due to 
overdiagnosis [5–7]; and (3) it may lead to repeat biopsies 
inducing increased infection rates [8]. Therefore, multi-
parametric MR imaging and MR-guided biopsy might be a 
better alternative.
Multi-parametric MR imaging (mpMRI) has recently 
emerged as a diagnostic technique that can accurately 
localize significant cancer in the prostate [9, 10]. In-bore 
MR-guided MR biopsy (MRgMRBx) has been shown to 
(1) reduce the detection of low-risk cancer and (2) increase 
the detection rate of intermediate- and high-risk cancer, 
while using fewer cores [11]. However, the associated cost, 
relative complexity, and inconvenience of MRgMRBx may 
Abstract 
Purpose To evaluate MR-targeted TRUS prostate biopsy 
using a novel local reference augmentation method.
Patients and methods Tracker-based MR–TRUS fusion 
was applied using local reference augmentation. In contrast 
to conventional whole gland fusion, local reference aug-
mentation focuses the highest registration accuracy to the 
region surrounding the lesion to be biopsied. Pre-acquired 
multi-parametric MR images (mpMRI) were evaluated 
using PIRADS classification. T2-weighted MR images 
were imported on an ultrasound machine to allow for MR–
TRUS fusion. Biopsies were targeted to the most suspi-
cious lesion area identified on mpMRI. Each target was 
biopsied 1–5 times. For each biopsied lesion the diameter, 
PIRADS and Gleason scores, visibility during fusion, and 
representativeness were recorded.
Results Included were 23 consecutive patients with 25 
MR suspicious lesions, of which 11 patients had a previ-
ous negative TRUS-guided biopsy and 12 were biopsy 
naïve. The cancer detection rate was 64 % (Gleason 
score ≥6). Biopsy was negative (i.e., no Gleason score) 
in seven patients confirmed by follow-up in all of them 
(up to 18 months). After MR–TRUS fusion, 88 % of the 
lesions could be visualized on TRUS. The cancer detection 
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prevent widespread adaption in clinical practice. An alter-
native biopsy method for MR-guided biopsy would be 
welcome.
MR-guided TRUS fusion biopsy (MRgUSBx) has 
recently emerged [12–14]. This allows to combine the 
high accuracy of mpMRI with the ease and accessibility of 
TRUS. However, for 95 % correct Gleason grading, a 1.9-
mm accurate spatial registration of MR and US is required 
[15]. Most MRgUSBx devices do not achieve this accuracy 
in practice (3–6 mm [12, 16]). Accuracy can be slightly 
increased by taking one or more additional cores [17].
Two MRgUSBx strategies can be distinguished: cogni-
tive and computational fusion. The fastest and simplest 
form of computational fusion is tracker-based rigid regis-
tration, using an electromagnetic (EM)-tracker [18, 19]. 
An EM-tracker attached to a TRUS probe tracks its posi-
tion and orientation allowing to link a live TRUS image 
to a prerecorded MR image. We previously performed a 
phantom study on EM-tracker registration and estimated 
the registration accuracy in 3D to be 5–7 mm [20]. Cur-
rent rigid MR–TRUS fusion protocols focus on optimiz-
ing accuracy for the entire gland volume. Due to prostate 
deformation, the registration accuracy can never be optimal 
within the whole gland. We hypothesize that by restricting 
the registration to the partial gland volume surrounding the 
lesion, a more consistent and possibly better registration 
accuracy can be achieved within this partial volume con-
taining the lesion. The EM-tracker approach we use in our 
study allows to do this quickly, which, combined with vis-
ual feedback, can lead in a few iterations to an augmented, 
focal match of TRUS and MR imaging. We propose a novel 
protocol to augment the accuracy locally by selecting ref-
erence landmarks on both MR and TRUS images that are 
close to the biopsy target [21], which we refer to as local 
reference augmentation in analogy to all-weather aircraft 
landing systems.
The aim of this study is to evaluate our novel EM-tracker 
MR–TRUS fusion biopsy protocol using local reference 
augmentation in regular clinical practice. To our knowl-
edge, this is the first report on a locally optimized MR–
TRUS fusion biopsy method. We will explore the capability 
of sampling mpMRI suspicious lesions and get insight into 
the representativeness of the biopsy result. Additionally, we 
will determine the proportion of tumors confidently visible 
on TRUS after fusion.
Patients and methods
Patient population
Inclusion criteria for our study were patients scheduled for 
MRgUSBx who had an mpMRI showing a lesion scored 
as PIRADS ≥4 or PIRADS 3 with additional clinical sus-
picion (e.g., unusually high PSA, persistent rising PSA). 
Biopsy was performed at the Radboudumc (Nijmegen, the 
Netherlands) or at the ZGT (Hengelo, the Netherlands). 
The study was approved by the Institutional Review 
Board of the Radboudumc for MR lesions >9 mm, and all 
included Radboudumc patients gave their written informed 
consent. The requirement to obtain institutional review 
board approval was waived at ZGT as MRgUSBx was 
their regular clinical procedure in prostate cancer diagno-
sis. Our data set contains all patients included at the Rad-
boudumc and ZGT between September 2013 and October 
2014.
Multi‑parametric magnetic resonance imaging
Prostate imaging mpMRI sequences were compliant to 
the ESUR guidelines [22] and included three orthogonal 
T2-weighted, diffusion-weighted, and dynamic contrast-
enhanced (DCE) series. Apparent diffusion coefficient 
(ADC) maps were calculated by the scanner. DCE used 
a gadolinium-based contrast agent by injecting 15 mL of 
Dotarem intravenously. Preferentially, we also added a 3D 
T2-weighted sequence with an isotropic resolution of 1 mm 
for MRgUSBx. Images of the entire prostate gland and 
seminal vesicles were obtained using a 3 Tesla MRI scan-
ner (MAGNETOM Trio or Skyra; Siemens, Erlangen, Ger-
many) with either a pelvic phased-array coil or a combina-
tion of an endorectal and pelvic phased-array coil.
Several genitourinary radiologists experienced in pros-
tate MRI prospectively evaluated the mpMRI in a regular 
clinical setting, using structured reporting with the ESUR-
standardized PIRADS classification [22]. The location of 
each lesion was stored on an in-house-developed mpMRI 
analysis, viewing and reporting workstation (ProCAD) 
[23]. All mpMRI evaluations were discussed in a consensus 
meeting and adapted if necessary.
Biopsy procedure
An Aplio 500 (Toshiba Medical Systems, Japan) ultrasound 
device with an end-firing transrectal transducer (PVT-
781VT; Toshiba Medical Systems, Japan) was used for the 
MRgUSBx. Previously obtained T2-weighted MR images 
were uploaded to the ultrasound device. The original 
mpMRI including PIRADS scores were displayed on our 
mpMRI workstation, available during the fusion procedure. 
For a peripheral zone lesion, the biopsy target was the dark-
est lesion region on ADC; for the transition zone, it was the 
most suspicious area on the T2-weighted series. The MR 
target location was first identified on the workstation dis-
playing the mpMRI and then re-located on the uploaded 
T2-weighted image.
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Patients were positioned in the left lateral position for 
biopsy, similar to USgBx. The TRUS probe was inserted 
rectally with gel. A needle guide was placed onto the trans-
ducer. The ultrasound machine had a SmartFusion option 
that includes an EM position sensor attached to the TRUS 
transducer to spatially correlate imported 3D MR images 
and US in real time. The SmartFusion EM-tracker-based 
fusion is a two-step process. First, the US scanning ori-
entation is matched to a variable MR image-reformatted 
orientation by manually selecting the best matching refor-
matting angle. Secondly, the correct anatomical 3D posi-
tion is linked by selecting the same reference anatomical 
landmark in both images. During the biopsy procedure, 
the live US and the pre-acquired transversal T2-weighted 
images were shown simultaneously, allowing MR image 
guidance (example shown in Fig. 1). The accuracy of the 
EM-based method was enhanced by our novel local refer-
ence augmentation, i.e., the reference landmark used for 
synchronizing 3D position was selected close to the target 
location as identified on MR (example shown in Fig. 2). 
Fig. 1  a Screenshot of the Toshiba Aplio 500 during MRgUSBx. 
The green circle indicates the target as reported on mpMRI, projected 
on the US image after fusion. The dotted green line indicates trajec-
tory along which the needle will shoot in the prostate (to be moved 
slightly for correct targeting in this screenshot). b The corresponding 
mpMRI with from left to right the transversal T2-weighted image, 
ADC map, and DCE image. These images were displayed using Pro-
CAD and were available during the fusion procedure
Fig. 2  Screenshot of the Toshiba Aplio 500 demonstrating the use of 
anatomical landmarks used for local reference augmentation. Refer-
ence landmarks are (iteratively) selected close to the target location. 
This example shows a cyst (indicated by the white arrow) inside the 
lesion (segmented in red)
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The MR-identified lesion location is then re-located on 
ultrasound using the fused image display. Visible mis-
match was minimized by repeating the landmark selection, 
compensating for landmark localization errors or patient 
movement. In case the lesion was visible on TRUS after 
initial fusion, the biopsy was targeted to the TRUS loca-
tion. Note that visibility in this respect means that lesions 
become visible on ultrasound only during the MR targeting 
fusion procedure. They are much less visible on ultrasound 
as such without the aid of fusion. Each mpMRI-detected 
target was biopsied 1–5 times. MR–TRUS fusion screen-
shots were stored during the biopsy to record the exact 
needle core location as part of the procedure to assess the 
representativeness.
Histopathology
Similar to all prostate biopsy procedures, all biopsy core 
specimens were examined by one of two specialized uro-
genital pathologists and graded according to the 2005 Inter-
national Society of Urological Pathology Modified Gleason 
Grading System [24]. For stratification of biopsy data into 
significant and insignificant cancer, we applied the crite-
ria for MRgMRBx as published by Pokorny et al. [11]. In 
short, lesions with a Gleason score ≥7 in at least one of 
the MRgUSBx cores were defined as being clinically sig-
nificant, as well as high-volume Gleason 3+3 (i.e., tumor 
length >6 mm or more than 2 positive cores). Low-volume 
Gleason 3+3 or Gleason scores <6 were considered clini-
cally insignificant, and lesions for which no Gleason score 
could be determined were considered negative. The cancer 
detection rate was based on lesions with Gleason score ≥6. 
The pathology results were correlated with the MR–TRUS 
fusion biopsy images and the original mpMRI study.
Biopsy evaluation
A urologist in consultation with a radiologist evaluated the 
pathological outcome of the biopsy, taking the PIRADS 
scores of the mpMRI into consideration. In case the patho-
logical outcome is lower than what would be expected based 
on mpMRI, the patient would need a re-biopsy. The biopsy 
was considered representative if the patient was not sched-
uled for an immediate MRgMRBx re-biopsy. As part of the 
radiological quality control procedure, all mpMRI studies 
that did not have significant cancer after MRgUSBx were re-
evaluated by two expert prostate radiologists in consensus. 
Furthermore, follow-up results of patients were collected.
Data analysis
As an indication of feasibility, the cancer detection rate 
and number of non-representative biopsies were analyzed. 
Earlier research indicated that PIRADS and Gleason 
score, as well as visibility and lesion size, had an effect 
upon the detection rate, and therefore we also performed 
subgroup analyses. Statistical proportion analysis was 
performed to determine the cancer detection rate for each 
(sub)group. Three different size groups were created 
(0–10, 11–20, and ≥20 mm). Finally, the mean number of 
cores taken per lesion was determined for each size group.
Results
Between September 2013 and October 2014, 23 consecu-
tive patients with 25 mpMRI suspicious lesions under-
went MRgUSBx and were included (two patients had two 
lesions). Table 1 summarizes the general characteristics 
of the included patients. Eleven patients had at least one 
previous negative TRUS biopsy session, one patient had a 
previous negative MRgMRBx 1 week before MRgUSBx 
(but representativeness of MRgMRBx was uncertain), and 
the other 11 patients were biopsy naïve. The prospective 
mpMRI scores were: 3 PIRADS 3 lesions, 9 PIRADS 4 
lesions, and 13 PIRADS 5 lesions. Most of the mpMRI 
suspicious lesions were located in the peripheral zone 
(20/25).
All MRgUSBx were considered representative, none 
needed an immediate re-biopsy. Table 2 shows the results 
Table 1  Summary of patient characteristics
Parameter All patients, n = 23
Mean SD Median Range
Age (years) 63 6.4 65 51–75
PSA (ng/mL) 10.3 6.2 8.9 2.9–29.3
Table 2  Results of prostate biopsies
Parameter Value
No. of patients/lesions 23/25
No. of patients/lesions with cancer (GS ≥6) 16/16
Total no. of cores 64
No. of positive cores (GS ≥6) 28
Mean primary Gleason grade 3.19 ± 0.39
Mean secondary Gleason grade 3.25 ± 0.43
Mean Gleason score (GS) 6.43 ± 0.50
No. of GS 3+3 9 (of which 4 were 
clinically signifi-
cant)
No. of GS 3+4 4
No. of GS 4+3 3
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of the prostate biopsies. In summary, the median num-
ber of targeted cores taken per lesion was 2 (range 1–5). 
Cancer (Gleason score ≥6) was detected in 16 of the 25 
lesions (64 %) and 16 of 23 patients (70 %). Two patients 
had a second lesion with Gleason score ≥6. MRgUSBx 
was negative in 7 patients: 2 had a PIRADS 5 lesion, 4 
had a PIRADS 4 lesion, and 1 had a PIRADS 3 lesion. 
Patients with negative MRgUSBx were referred to active 
surveillance based on PSA or follow-up mpMRI after 
3–6 months.
The cancer detection rates per PIRADS score are shown 
in Table 3. The cancer detection rate of the PIRADS 5 
lesions was 77 %, of PIRADS 4 lesions 44 %, and of the 
PIRADS 3 lesions 67 %. Pathological biopsy outcomes per 
PIRADS score are shown in Fig. 3a. Clinically significant 
lesions were present in 46, 33, and 67 % of the PIRADS 5, 
4, and 3 lesions, respectively.
During the biopsy procedure, 23 of the lesions (88 %) 
could be visualized on TRUS after image registration. For 
TRUS visible lesions, biopsies were targeted to the location 
as visible on TRUS. The cancer detection rate of the TRUS 
visible lesions was 64 % and that of the TRUS invisible 
lesions 67 % (see Table 3). For clinically significant cancer, 
this changes to 45 and 33 % for TRUS visible and invisible 
lesions, respectively. The pathological outcomes for TRUS 
visibility are shown in Fig. 3b.
In Table 4 the lesions are grouped according to their size. 
The cancer detection rate is higher for the larger lesions, on 
both lesion and core basis. For lesions larger than 10 mm, 
the cancer detection rate is 73 % (Gleason score ≥6). Also, 
slightly more cores are taken for larger lesions.
The follow-up of the mpMRI suspicious patients 
with a negative or insignificant MRgUSBx outcome 
was collected, and results are shown in Table 5. In sum-
mary, follow-up results showed that 3 of 7 patients with 
negative MRgUSBx had stable or decreasing PSA after 
6–18 months and one patient is in active surveillance. 
For the remaining three, one had negative USgBx after 
12 months, one had negative MRgMRBx after 12 months, 
and one showed a PIRADS 2 lesion on follow-up mpMRI. 
For the five patients with insignificant MRgUSBx, one 
patient was lost to follow-up, one patient has decreasing 
PSA, one patient is scheduled for biopsy, and two are still 
in active surveillance.
Table 3  Cancer detection rates per PIRADS score and TRUS lesion visibility, including 95 % confidence intervals (CI)
Category No.  
of lesions
No. of lesions  
with any cancer
Proportion  
(95 % CI) any cancer
No. of lesions  
with significant cancer
Proportion (95 % CI) 
significant cancer
PIRADS 3 3 2 67 % (20–94 %) 2 67 % (20–94 %)
PIRADS 4 9 4 44 % (19–73 %) 3 33 % (12–65 %)
PIRADS 5 13 10 77 % (49–93 %) 6 46 % (23–71 %)
TRUS visible 22 14 64 % (43–80 %) 10 45 % (27–65 %)
TRUS invisible 3 2 67 % (20–94 %) 1 33 % (6–80 %)
All 25 16 64 % (44–80 %) 11 44 % (27–68 %)
Fig. 3  The number of lesions detected with targeted MRgUSBx 
according to a the PIRADS score on mpMRI and b the visibility of 
the lesion on TRUS
1042 Int Urol Nephrol (2016) 48:1037–1045
1 3
Discussion
Prostate cancer (Gleason score ≥6) was detected in 64 % 
of the lesions biopsied and in 70 % of the patients. All 
biopsies were representative showing that our novel local 
reference augmented method is feasible in clinical practice. 
During MR–TRUS fusion, 88 % of the lesions could be 
visualized on TRUS alone, allowing targeted biopsies to be 
optimized using live TRUS guidance. The cancer detection 
rate increases with increasing tumor size.
The representativeness of the mpMRI suspicious, but 
negative MRgUSBx was confirmed by follow-up; i.e., none 
of the seven negative MRgUSBx patients revealed clini-
cally significant pathology. The detection rate for clinically 
significant cancer (44 %) was lower than the 65 % shown 
by Pokorny et al. [11] for MRgMRBx. Three reasons can 
be pointed out for this difference: (1) different patient 
population between studies; (2) difference in biopsy tech-
nique; and (3) difference in expertise of the radiologist(s). 
In Pokorny et al. three expert radiologists in consensus 
evaluated the mpMRI, which in our study was done by the 
attending prostate radiologist. To investigate the first two 
points, more research is required comparing MRgUSBx to 
MRgMRBx with similar patient populations. To investigate 
the third point, two expert radiologists in consensus re-
evaluated the original mpMRIs with negative and clinically 
insignificant MRgUSBx. Table 5 shows that the original 
mpMRI assessment may indeed have overestimated tumor 
aggression: 43 % (6/14) of the lesions were downgraded 
during retrospective re-evaluation by experts. This con-
firms that expertise is important. In case subsequent biopsy 
reveals no clinically significant cancer in PIRADS 4 and 5 
lesions, it is very important to re-evaluate the quality of the 
mpMRI, the reading, and the subsequent biopsy technique.
The original results of our locally optimized EM-based 
registration method are well in line with results of other 
EM-based systems, which have a cancer detection rate 
between 49 and 69 % [18, 19]. Clinical studies with other 
MR–TRUS fusion systems also show similar detection rates 
[18, 19, 25, 26]. However, patient populations differ quite a 
bit between the different studies, e.g., regarding the amount 
of patients with a previous negative biopsy or patients that 
were biopsy naïve. Although our initial results are similar 
to previously published results, more research is needed 
to investigate whether local reference augmentation is an 
actual technical improvement to current MR–TRUS fusion 
methods.
We know from previous phantom studies that our EM-
based registration method has a registration accuracy of 
about 5 mm [20]. Yet we were still able to achieve reason-
able detection rates in the 0–10 mm category. The follow-
ing items played a role. First, we enhanced the EM-based 
registration technique by locally optimizing fusion through 
the iterative selection of anatomical landmarks close to the 
target. Secondly, the number of biopsy cores was increased 
in case the performing physician was not certain about the 
biopsy taken. By taking more cores per target, the tumor 
hit rate increases [17]. Thirdly, during the MRgUSBx we 
noticed that 88 % of the targets became visible on TRUS 
images during MR–TRUS fusion. In case the targets 
become visible on TRUS, these can be more accurately tar-
geted even if the registration is not optimal [27]. The TRUS 
visibility is often subtle and may very well depend on the 
quality of the ultrasound images.
The cancer detection rate increases with increasing 
lesion size, which might be an indication that the smaller 
lesions are harder to hit with MRgUSBx and might bet-
ter be biopsied with MRgMRBx. For lesions larger than 
10 mm diameter, our results show a cancer detection rate of 
73 %, approaching the results of MRgMRBx.
The main limitation of our study is the small number 
of patients. But sufficient to indicate that MR–TRUS 
fusion with local reference augmentation is feasible 
for targeting prostate biopsies. To investigate whether 
MRgUSBx is a viable alternative to MRgMRBx, a 
non-inferiority trial setting including more patients is 
required. Then, similar patient groups can be compared 
and it can be determined whether MRgUSBx is non-infe-
rior to MRgMRBx.
To summarize, MR–TRUS fusion biopsy using local 
reference augmentation is feasible. This is especially the 
case for lesions with an mpMRI maximum diameter of at 
least 10 mm or PIRADS 5 lesions. Smaller lesions may still 
require in-bore MR-guided biopsy.
Table 4  Biopsy outcomes grouped according to lesion size on mpMRI
Largest  
diameter (mm)
No.  
of lesions
Mean no.  
of cores (range)
Cancer (GS ≥6)  
detection rate per lesion (95 % CI)
Cancer (GS ≥6)  
detection rate per core (95 % CI)
0–10 10 2.4 (2–3) 50 % (24–76 %) 33 % (18–53 %)
11–20 11 2.5 (1–5) 64 % (35–85 %) 44 % (28–63 %)
>20 4 2.8 (2–4) 100 % (45–100 %) 73 % (43–91 %)
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